Key takeaways: AI’s ability to quickly analyze and integrate vast, diverse data, identify patterns, and make accurate predictions presents significant opportunities in clinical research and drug development. Advanced analytics, predictive modeling, and machine...
Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million...
In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions. No where is this more evident than in oncology, where RWD and RWE are delivering on four key...
Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare...
In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders...
The use of real-world evidence (RWE) in regulatory decision-making and health technology assessments (HTA) is gaining traction, particularly in the evolving landscape of oncology pharmacotherapeutics in Europe where navigating the drug approval and market access...